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Abstract
Objective: Blood-based biomarkers for neurodegenerative conditions could
improve diagnosis and treatment development. Neurofilament light chain
(NfL), a marker of axonal injury, is elevated in cerebrospinal fluid (CSF) of
patients with progressive supranuclear palsy (PSP). The goal of this study was
to determine the diagnostic and prognostic value of plasma NfL in patients
with PSP. Methods: Plasma NfL was measured with ultrasensitive digital
immunoassay-based technology at baseline and 1-year follow-up in a pilot
cohort of 15 PSP patients and 12 healthy controls, and a validation cohort of
147 PSP patients. Mixed linear models tested the ability of plasma NfL to pre-
dict neurological, cognitive and functional decline, and brain atrophy. Results:
Baseline mean plasma NfL levels were elevated in PSP patients (31  4 pg/mL,
vs. control, 17.5  1 pg/mL, P < 0.05) and this difference persisted at follow-
up. A cutoff value of 20 pg/mL related to the diagnosis of PSP with a sensitivity
of 0.80 and specificity of 0.83 (positive likelihood ratio = 4.7 and a negative
likelihood radio of 0.24). Patients with higher NfL levels had more severe neu-
rological (PSPRS, 36.9% vs. 28.9%, P = 0.04), functional (SEADL, 38.2%
vs. 20%, P = 0.03), and neuropsychological (RBANS, 23.9% vs. 12.3%,
P = 001) deterioration over 1 year. Higher baseline NfL predicted greater
whole-brain and superior cerebellar peduncle volume loss. Plasma and CSF NfL
were significantly correlated (r = 0.74, P = 0.002). Interpretation: Plasma NfL
is elevated in PSP and could be of value as a biomarker both to assist clinical
diagnosis and to monitor pharmacodynamic effects on the neurodegenerative
process in clinical trials.
Introduction
Progressive supranuclear palsy (PSP) is a cause of atypical
parkinsonism associated with deposition of primarily 4
microtubule binding domain repeat (4R) tau and neuronal
loss, most prominently in the brainstem, basal ganglia, and
cerebellum, with variable cortical involvement.1 PSP has
an estimated prevalence of 5.8–6.5 cases per 100,000 indi-
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viduals, and most commonly presents after age 40 with
gait instability, recurrent falls, and eye movement abnor-
malities.2,3 No effective treatments are available for PSP
and mortality is usually associated with falls and bron-
choaspiration, with a median survival of 7 years.4 Develop-
ment of effective therapies has been hindered by the lack
of sensitive tools to diagnose the disease and quantify dis-
ease activity and progression in clinical trials. Magnetic
resonance imaging (MRI) and positron emission tomogra-
phy have been used in the diagnosis of PSP, but these have
suboptimal sensitivity and specificity, limited availability,
and high cost.4 Development of sensitive fluid biomarkers
could advance early detection and therapeutic develop-
ment for PSP.
Neurofilament light chain (NfL) has shown consistent
cerebrospinal fluid (CSF) elevations in PSP and other dis-
orders associated with atypical parkinsonism, compared
to healthy controls and patients with idiopathic Parkin-
son’s disease (PD).5–7 In a recent PSP clinical trial, CSF
NfL increased over 1 year and changes correlated with
progression of ocular motor deficits and superior cerebel-
lar peduncle (SCP) atrophy.8 NfL is the smallest interme-
diate filament protein of neurons, and it contributes
axonal structure, mechanoresistance, and scaffolding for
organelle organization.9 Elevated NfL concentrations in
CSF are believed to reflect neurodegeneration-associated
axonal injury, and have been documented in demyelinat-
ing disease and brain trauma.9–11 CSF NfL is believed to
reflect extracellular brain concentrations, but blood-based
quantification of NfL is highly desirable, since sample col-
lection is comparatively more accessible and inexpensive.
Recent studies have demonstrated the feasibility of blood
NfL quantification in neurological conditions such as
multiple sclerosis, amyotrophic lateral sclerosis (ALS),
and Alzheimer’s disease (AD).12–14 Such studies, however,
have been based on standard immunoassays, which lack
the analytical sensitivity to quantify NfL except in samples
with very high concentrations. For this reason, we set out
to develop an NfL assay based on the ultrasensitive Single
Molecule Array (Simoa) technique.15 Further, no prior
attempts have been made for assessing the clinical value
of blood NfL concentrations in PSP.
The goal of this study was to measure plasma NfL con-
centrations using an ultrasensitive digital array-based
technology to determine the diagnostic and prognostic
value of plasma NfL in PSP. An original cohort was used
to determine the differences in plasma NfL concentrations
between PSP patients and healthy controls and their abil-
ity to predict dementia severity upon follow-up after
1 year. A separate validation cohort of PSP patients from
a large, international clinical trial8 further examined the
ability of plasma NfL levels to predict clinical decline and
MRI-based measures of brain atrophy over 1 year.
Subjects and Methods
Participants
This retrospective study was conducted in an original
cohort of volunteers evaluated at the University of Cali-
fornia, San Francisco Memory and Aging center (UCSF
cohort, n = 27). Analyses were also performed in a vali-
dation cohort consisting of patients with PSP recruited
for a previously published international multicenter clini-
cal trial8 (Allon cohort, n = 147). Patients with PSP met
NINDS-Society for Progressive Supranuclear Palsy diag-
nostic criteria for probable or possible PSP.16 PSP patients
and controls were included if two plasma samples were
available with a resampling interval of 365  90 days.
CSF values for beta amyloid, total tau, and NfL were
available only in seven subjects in the UCSF cohort and
in 22 subjects in the Allon cohort. Plasma and CSF sam-
ples were collected on the same day. Neuropathological
diagnosis was available in six of the 15 cases at the UCSF
cohort. All six cases had PSP pathology. Volumetric MRI
data8 were available from 124 Allon cohort patients. All
patients provided informed consent at the time of recruit-
ment and procedures were approved by the UCSF Institu-
tional Review Board.
Plasma and CSF analyses
Blood samples were collected by venipuncture in ethyle-
nediaminetetraacetic acid (EDTA) tubes for plasma. After
centrifugation, plasma samples were aliquoted and stored
at 80°C. Plasma NfL levels were determined using the
NF-Light kit from UmanDiagnostics (UmanDiagnostics,
Umea, Sweden), transferred onto the Simoa platform
using a homebrew kit (Quanterix Corp, Boston, MA).
The lower limit of quantification (LLOQ), determined by
the blank mean signal + 10 SD, was 1.95 pg/mL. All sam-
ples measured well above the LLOQ. The analyses were
performed by a board-certified laboratory technician
using one batch of reagents with intra- and interassay
coefficients of variation below 10% and 15%, respectively.
Samples from both cohorts were analyzed using the same
NfL-Light kit batch. In the Allon cohort, lumbar punc-
tures were performed for CSF collection and NfL mea-
surement using an enzyme-linked immunosorbent assay
(ELISA) as described previously.7
Clinical measures
Neurological assessments were based on the Progressive
Supranuclear Palsy Rating Scale (PSPRS).8,17 The Mini-
Mental State Examination (MMSE)18 was obtained at
baseline in all subjects. In the Allon cohort, the Repeat-
ª 2016 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association. 217
J. C. Rojas et al. Neurofilament Light Chain in PSP
able Battery for the Assessment of Neuropsychological
Disease Severity (RBANS) was used to measure neuropsy-
chological status.19 Assessment for overall disability was
completed with the Clinical Dementia Rating Sum of
Boxes scale (CDR-sb)20 in the UCSF cohort and with the
Schwab and England Activities of Daily Living (SEADL)
scale21 in the Allon cohort. The CDR-sb was measured at
baseline and 52 weeks. The PSPRS and SEADL scales
were obtained at baseline and at 6, 13, 26, 39, and 52
weeks visits. The RBANS was obtained at baseline and at
26 and 52 weeks visits.
Volumetric MRI data
Whole-brain, ventricular, midbrain, and SCP volumetric
measures obtained from 1.5 or 3 T structural MRI scans
were available in the Allon group. MRI scans met stan-
dards established by the Mayo Clinic’s Aging and Demen-
tia Imaging Research laboratory and volumetric data were
generated using the Boundary Shift Integral technique or
label propagation in voxel-based morphometry (SPM5) as
described previously.8
Statistics
Tests for normality were conducted with the Shapiro–
Wilk test. Means were compared with independent sam-
ples t-test and expressed with their associated standard
error of the mean. If data were not normally distributed,
they were analyzed with the Mann–Whitney U test or
chi-square test when appropriate and expressed with their
associated confidence interval. Contingency matrices used
data from the UCSF cohort to determine the sensitivity
and specificity of the plasma NfL in the diagnosis of PSP.
Classification of controls and patients based on plasma
NfL levels was tested by means of principal component
analysis with inclusion of baseline characteristics (i.e., age,
gender, education level, MMSE, CDR-sb, and plasma
NfL). Baseline plasma NfL levels were dichotomized using
a median split for evaluation of the relationship with
changes in clinical and imaging variables.
In the validation Allon cohort, the ability of baseline
plasma NfL to predict a change in clinical measures at 6,
13, 26, 39, and 52 weeks was assessed with age, gender,
and baseline MMSE-adjusted mixed linear models with
PSPRS, SEADL, and RBANS scores as dependent vari-
ables. In these analyses, baseline plasma NfL was intro-
duced as a categorical measure (dichotomized at the 50th
percentile value). In a second series of analyses, baseline
plasma NfL was also introduced as a continuous variable.
Age- and gender-controlled Pearson’s partial correlations
were determined between baseline plasma NfL levels and
changes in regional and whole-brain volume. Pairwise
correlations were used to assess the relationship between
plasma and CSF NfL levels. For all analyses, a P < 0.05
was considered significant. Data were analyzed using SPSS
(version 23; SPSS/IBM, Chicago, IL).
Results
Plasma NfL levels differentiate PSP patients
from controls
PSP patients had baseline mean plasma NfL levels
(31  4 pg/mL) that were nearly twice as high as those
of controls (17.5  1 pg/mL, P < 0.05). This difference
between controls and PSP patients persisted at 1-year fol-
low-up (Fig. 1A). Principal component analysis revealed
that classification of baseline plasma NfL values into low
and high medians was the most important clinical vari-
able contributing to the prediction of diagnosis (score
coefficient for Component 1: baseline NfL 0.41 and base-
line CDR-sb 0.36) (Fig. 1B). The cutoff value of 20 pg/
mL related to the diagnosis of PSP with a sensitivity of
0.80 and specificity of 0.83. At this cutoff value, elevated
plasma NfL had a positive likelihood ratio of 4.7 and a
negative likelihood radio of 0.24. Tables 1, 2 summarize
baseline demographic, clinical, imaging, and biomarker
characteristics for participants in the UCSF and Allon
cohorts, respectively. Certain baseline demographic fea-
tures such as age and gender influenced baseline plasma
NfL levels. There were more female participants in the
UCSF cohort, but the between-group differences in
plasma NfL were not confounded by gender effects. The
proportion of male-to-female participants was similar in
control and PSP groups, and the gender differences in
baseline plasma NfL levels were not significant in either
group (control, P = 0.25) or PSP (PSP, P = 0.25). In
addition, gender did not influence baseline or follow-up
plasma NfL levels in the Allon cohort. Gender was also
used as a covariate in mixed linear analyses.
High baseline plasma NfL levels in PSP
predict worse functional status at 1-year
follow-up
A median split of baseline plasma NfL values from the
UCSF cohort PSP group was used to define PSP patients
with low (<28.4 pg/mL) and high (≥28.4 pg/mL) baseline
levels. This median split within the PSP group was imple-
mented because a median split was highly sensitive to
classify controls and patients. PSP patients with baseline
plasma NfL levels in the upper median for the PSP group
had a higher CDR-sb score at 1-year follow-up compared
to baseline (PSP patients 6.7 [CI: 3.5–9.6] vs. controls 4.1
[CI: 2.5–5.6] 1-year follow-up, P = 0.04) (Fig. 2). There
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was no significant 1-year interval change in the CDR-sb
score in PSP patients with baseline plasma NfL levels in
the lower median (3.3 [CI: 0.82–5.8] baseline NfL vs. 3
[CI: 0.6–5.3] 1-year follow-up, P = 0.33).
In a validation cohort, high baseline plasma
NfL levels in PSP patients predict more
severe neurologic, cognitive, and functional
decline at 1-year follow-up
Mean baseline plasma NfL levels in PSP patients were
higher in the Allon cohort than in the UCSF cohort
(43.7  2 pg/mL vs. 31  4 pg/mL, respectively,
P = 0.01). Therefore, we derived new low and high base-
line plasma NfL levels based on a median split (<36.7 pg/
mL vs. ≥36.7 pg/mL) of values from this group. Similar to
the original cohort, PSP patients with high baseline plasma
NfL levels had higher levels at 1-year follow-up compared
to those with low baseline levels (Table 2). Plasma NfL
levels positively correlated with CSF NfL levels at baseline
(r = 0.70, P = 0.001) and at year-1 follow-up (r = 0.74,
P = 0.002) (Fig. 3). Mixed linear models assessed the abil-
ity of baseline plasma NfL levels, to predict the annual
change in neurologic, cognitive, and functional status, as
measured with PSPRS, RBANS, and SEADL, respectively
(Fig. 4). Overall, PSPRS scores worsened as a function of
time, and baseline NfL plasma concentrations higher than
the median predicted a more severe worsening over time,
compared to those with plasma NfL lower than the median
(P = 0.02). A time-by-group interaction supported signifi-
cant worsening by the end of the year in patients in the
high baseline plasma NfL level group (P = 0.04): the per-
cent change difference in the PSPRS score between high
and low baseline plasma NfL groups was 5.5 points at week
13 (7.3% [CI: 11.8 to 2.8] vs. 1.7% [CI: 6.2 to
2.6], respectively), and by week 52, it increased to 7.6
points (36.5% [CI: 44.3 to 28.8] vs. 28.9% [CI:
35.9 to 22], respectively). Similarly, compared to
patients in the lower median, patients with higher baseline
plasma NfL had a more rapid decline in functional status,
as measured by the SEADL scale (P = 0.03). The mean
percent change in the SEADL score at week 52 was 38%
(CI: 45.5 to 30.6) in the high NfL level group, but only
20.2% (CI: 31.8 to 8.6) in the lower median group.
High baseline plasma NfL also predicted a faster decline in
neuropsychological performance at 1 year (P = 0.007). A
significant time-by-group interaction was observed for the
decline in the RBANS score (P = 0.001). Upon 1-year fol-
low-up, the decline in the RBANS score in patients with
high NfL levels was 23.9% (CI: 18.4–29.3), whereas it was
only 11.8% (CI: 7.9–15.7) in those with low baseline NfL
levels. When treated as a continuous variable, baseline NfL
predicted SEADL (P = 0.003) and RBANS scores
(P = 0.002), and terms for time by group interactions were
significant for the prediction of PSPRS (P = 0.03) and
RBANS scores (P = 0.001).
Mean baseline plasma NfL values for PSP patients in
the Allon cohort were 29.1% higher than in the UCSF
Figure 1. Plasma NfL is elevated in PSP patients, UCSF cohort. (A) Plasma NfL concentrations in control (blue) and PSP (red) patients at baseline
and follow-up. In both groups, NfL levels remained constant overtime, but they were comparatively elevated and showed wider variability in PSP
patients. Thick horizontal bars represent the median. Upper and lower box limits represent the 75th and 25th percentiles. Error bars represents
the minimum and maximum values. Individual data points, including extreme values, appear to the left of each box. (B) Principal component
analysis showing classification of PSP patients (red circles) from healthy controls (blue circles) with high accuracy. Clustering was observed on
“Component 1” axis which contained baseline NfL level as the major contributing factor. Major contributing variables on “Component 2” were
age and education level. *Significant within-group difference, P < 0.05. NfL, neurofilament light chain; PSP, progressive supranuclear palsy.
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cohort. This difference was likely explained by differences
in the clinical features of patients in the two cohorts. For
example, comparison of available baseline CSF total tau
levels showed that PSP patients in the Allon cohort had
levels 21% lower (55.2  5 pg/mL vs. 69.9  3 pg/mL
P = 0.01) and CSF NfL levels 42% higher (4849  617
vs. 2789  455 P = 0.04) than those in the UCSF cohort.
We have previously shown that CSF tau levels are lower
in PSP than controls, and relatively lower CSF tau con-
centrations would be consistent with greater severity.7 In
addition, mean baseline PSPRS scores in the UCSF cohort
(36 [CI: 27.7–44.2]) were numerically higher (P = 0.39)
than the Allon cohort (39.4 [CI: 37.4–41.4]). After log
transformation and normalization of plasma values from
both cohorts, baseline NfL values in PSP patients in the
Allon cohort also differed from control values in the
UCSF cohort. These transformed values also significantly
predicted changes in clinical variables at 1-year follow-up
(not shown).
Baseline plasma NfL levels predict changes
in whole-brain and PSP-related regional
brain volumes
Patients with high baseline NfL had greater magnitudes of
reduction in whole-brain volume compared to those with
lower baseline NfL levels. A higher degree of volume
change at 1-year was also observed in the SCP of patients
with high baseline NfL compared to those with low base-
line NfL (Fig. 5).
Discussion
This report presents proof of concept that plasma NfL
concentrations are quantifiable and elevated in PSP
patients compared to age-matched healthy individuals.
NfL concentrations in PSP patients were twice as high as
those in controls, and a median cutoff value of 20 pg/mL
allowed differentiation of patients and controls with a
high level of accuracy. Plasma NfL levels in PSP patients
consistently correlated with CSF NfL levels. NfL levels
were also useful in predicting clinical progression of PSP.
PSP patients with higher baseline NfL levels had a more
rapid functional decline compared to patients with low
baseline NfL levels. Prediction of functional decline over
1 year was observed in both the original and validation
cohorts. NfL levels were sensitive for detection of patients
with worse neurological progression, functional decline,
and brain atrophy. Differences in the PSPRS scores
between PSP patients with high and low baseline NfL
levels were observed as early as at 6-weeks follow-up.
Higher baseline plasma NfL levels also predicted more
severe whole-brain and SCP atrophy at 1-year follow-up.
The findings suggest that plasma NfL could be a useful
biomarker for assessing disease severity and predicting
disease progression in PSP. High baseline plasma NfL
levels were associated with a more severe neurological,
functional, and cognitive decline at 1 year. The clinical
predictive value of NfL is consistent with findings from
the davunetide in PSP trial, in which a post hoc analysis
in a subset of patients (n = 19) revealed that longitudinal
CSF NfL increases correlated with worsening of clinical
ocular motor ratings on the PSPRS.8 Similarly, CSF NfL
Table 1. Demographic, clinical, and plasma neurofilament light-chain
characteristics of study participants, UCSF cohort.
Control
(n = 12)
PSP
(n = 15) P-value
Demographics
Age at sampling, year,
mean (SD)
70 (8) 66.4 (6) 0.20
Gender, N, male/female 2/10 5/10 0.40
Education, year, mean (SD) 18 (2) 15 (2) 0.008
Baseline MMSE, mean (SD) 29.4 (0.7) 27.3 (1) 0.002
Baseline CDR-sb, mean, (SD) 0 (0.1) 3.7 (2) <0.001
Levodopa dose equivalent,
mg/day, mean (SD)
0 282 (301) <0.001
Interval between plasma
samples, day, mean (SD)
348 (40) 369 (30) 0.13
Baseline CSF total tau,
pg/mL, mean (SD)1
N/A 69.9 (9) N/A
Baseline CSF NfL,
pg/mL, mean (SD)1
N/A 2789 (1206) N/A
Mean baseline plasma NfL levels, pg/mL (SD)
Total 17.5 (5) 31 (17) 0.001
Age at sampling, year
56–67 15.2 (2) 25.6 (6) 0.004
68–82 19.1 (6) 39.2 (24) 0.02
Gender
Male 13.1 (1) 23 (5) 0.09
Female 18.3 (5) 34 (20) 0.003
MMSE
25–28 13.8 (2) 32.1 (19) 0.02
>28 18.2 (5) 28 (8) 0.07
Mean year-1 plasma NfL levels, pg/mL (SD)
Total 17.5 (3) 34.2 (16) <0.001
Age at sampling, year
56–67 15.2 (3) 28.3 (12) 0.001
68–82 19.2 (3) 43.1 (17) 0.001
Gender
Male 12.4 (0.1) 28.4 (12) 0.09
Female 18.5 (3) 37.1 (17) <0.001
MMSE
≤28 13.8 (1) 36.4 (17.6) 0.02
>28 18.3 (3) 28.1 (9) 0.02
PSP, progressive supranuclear palsy; MMSE, Mini-Mental State Exami-
nation; CDR-sb, Clinical Dementia Rating Sum of Boxes; CSF, cere-
brospinal fluid; NfL, neurofilament.; SD, standard deviation.
1Samples available for seven patients.
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Table 2. Demographic, clinical, and plasma neurofilament light-chain characteristics of patients with progressive supranuclear palsy, Allon cohort.
Low baseline NfL (n = 73) High baseline NfL (n = 74) P-value1 Total (n = 147)
Age at sampling, year, mean (SD) 66.6 (6) 67.7 (7) 0.35 67.1 (6)
Gender, N, male/female 34/39 44/30 0.13 78/69
Baseline MMSE, mean (SD) 26.5 (3) 25.7 (3) 0.27 26.1 (3)
Baseline PSPRS, mean (SD) 38.1 (13) 40 (11) 0.15 39.6 (12)
Baseline SEADL, mean (SD) 0.54 (0.2) 0.50 (0.2) 0.37 0.52 (0.24)
Baseline RBANS, mean (SD) 147 (32) 138 (35) 0.34 144.1 (34)
Baseline CSF total tau, pg/mL, mean (SD)2 55.3 (31) 55.2 (16) 0.99 55.2 (26)
Baseline CSF NfL, pg/mL, mean (SD)3 4036.5 (3074) 6272.8 (1995) 0.08 4887.3 (2962)
Whole-brain volume, mm3 9106, mean (SD) 1.29 (0.1) 1.25 (0.1) 0.07 1.2x106 (1.3x105)
Ventricles volume, mm3 9104, mean (SD) 4.58 (2.4) 4.81 (2) 0.20 4.6x104 (2.3x104)
Midbrain volume, mm3 9103, mean (SD) 6.99 (0.9) 6.61 (0.7) 0.01 6.8x103 (863)
SCP volume, mm3, mean (SD) 404.3 (111) 344.2 (94) 0.002 378.4 (108)
Volume change at 1 year, % median (CI)
Whole brain 0.6 (0.9 to 0.3) 1.0 (1.3 to 0.8) 0.02 0.8 (1.0 to 0.6)
Ventricles 8.2 (6.8–9.6) 11.5 (9.2–13.8) 0.05 9.7 (8.4–11)
Midbrain 3.0 (3.8 to 2.2) 3.7 (4.5 to 2.8) 0.28 3.3 (3.9 to 2.7)
SCP 4.5 (6.8 to 2.1) 9.1 (11.8 to 6.5) 0.005 6.6 (8.3 to 4.8)
Baseline CSF NfL level, pg/mL 9103, mean (SD) 4.03 (3) 6.27 (1.9) 0.08 4.8 (2.8)
Mean baseline plasma NfL levels, pg/mL (SD)
Total 26 (6) 61.2 (36) 43.7 (31)
Age at sampling, year
45–67 23.9 (6) 54.3 (19) 37.6 (20)
>67–84 28.5 (6) 66.8 (44) 49.7 (38)
P-value4 0.004 0.07 0.007
Gender
Male 27 (6) 55.8 (16) 43.3 (19)
Female 25 (7) 69.1 (52) 44.2 (33)
P-value4 0.24 0.60 0.11
MMSE
≤27 26.6 (7) 65.7 (44) 47.1 (38)
>27 25.3 (6) 55.3 (18) 39.6 (20)
P-value4 0.37 0.28 0.23
Mean year 1 plasma NfL levels, pg/mL (SD)
Total 35.3 (14) 69.3 (45) 52.4 (38)
Age at sampling, year
45–67 32 (11) 58.6 (24) 44 (22)
>67–84 39.3 (16) 77.9 (56) 60 (47)
P-value4 0.03 0.09 0.006
Gender
Male 34.2 (10) 64.1 (30) 51.1 (28)
Female 36.2 (16) 76.9 (62) 53.9 (47)
P-value4 0.98 0.40 0.84
MMSE
≤27 36.7 (13) 77 (55) 58.3 (46)
>27 33.8 (15) 58.1 (24) 45.4 (23)
P-value4 0.17 0.09 0.05
NfL, neurofilament; SD, standard deviation; MMSE, Mini-Mental State Examination; PSPRS, Progressive Pupranuclear Palsy Rating Scale; SEADL,
Schwab and England Activities of Daily Living scale; RBANS, Repeatable Battery for the Assessment of Neuropsychological Disease severity; CSF,
cerebrospinal fluid; SCP, superior cerebellar peduncle.
1Low baseline versus high baseline NfL between-group comparison.
2Fourteen samples available.
3Eight samples available.
4Within-group comparison.
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levels have been observed to correlate with more severe
parkinsonian symptoms, as measured with the Hoehn
and Yahr staging scale, but not with disease duration in
patients with PSP and PD.5 We have previously observed
elevations of CSF NfL in PSP patients compared to con-
trols.7 Although CSF NfL levels did not correlate with
clinical or neuropsychological ratings in PSP, high CSF
NfL levels were associated with higher CDR-sb and lower
MMSE scores in behavioral variant frontotemporal
dementia, semantic dementia, and nonfluent primary pro-
gressive aphasia.7 Multiple sclerosis patients with
increased CSF NfL levels also show significantly higher
clinical severity scores and elevated CSF lymphocyte cell
counts and oligoclonal bands.22 In contrast to the longi-
tudinal elevations observed in CSF NfL in the davutenide
trial,8 no significant within-group changes in plasma NfL
concentrations were observed with time in this study.
This was observed in the control and PSP groups in the
UCSF cohort and in the PSP group in the Allon cohort
(Tables 1, 2). Our findings are consistent with a recent
study in ALS patients, in which blood NfL levels did not
increase as a function of time, but maintained a relatively
constant expression.14 Nevertheless, Lu and colleagues
also observed that plasma NfL distinguished ALS patients
from healthy controls with sensitivity of 0.90 and speci-
ficity of 0.71, and ALS patients with higher baseline blood
NfL had an increased mortality hazard ratio.14 Together,
these findings support that plasma NfL may be of value
in monitoring disease progression, although whether
levels change over time within subjects will require fur-
ther study. The findings also suggest that plasma NfL
could be a useful theragnostic biomarker in PSP clinical
trials of drug candidates with disease-modifying potential.
In this study, plasma NfL levels at baseline also pre-
dicted changes in global and regional brain volume
Figure 2. Plasma NfL levels predict cognitive function at 1-year
follow-up in PSP, UCSF cohort. CDR-sb scores at baseline (blue) and
follow-up (red) in patients in the low and high median baseline
plasma NfL. No change over time is seen in the low baseline group,
whereas a significant CDR-sb score worsening is observed in PSP
patients in high baseline plasma NfL levels. Thick horizontal bars
represent the median. Upper and lower box limits represent the 75th
and 25th percentiles. Error bars represents the minimum and
maximum values. Individual data points appear to the left of each
box. *Significant within-group difference, P < 0.05. NfL,
neurofilament light chain; PSP, progressive supranuclear palsy; CDR-
sb, clinical dementia rating sum of boxes.
Figure 3. Plasma NfL levels correlate with CSF NfL levels in PSP, Allon
cohort. The graph shows plasma and their correlations with CSF NfL
values at (A) baseline (n = 20) and (B) 1 year follow-up (n = 14). NfL,
neurofilament light chain; CSF, cerebrospinal fluid; PSP, progressive
supranuclear palsy.
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detected by MRI. Greater rates of volume loss were
observed at 1 year in the SCP in patients with high
baseline plasma NfL. The SCP is mainly formed by the
dentatorubrothalamic tract, a white matter structure that
has been shown to undergo severe and selective neurode-
generative changes in PSP, compared not only to normal
controls, but also to patients with other forms of atypical
parkinsonism.23 In addition, partial correlation analyses
revealed a biologically relevant relationship between
plasma NfL levels and the amount of brain atrophy at
1 year (Fig. 5). In agreement with these data, changes in
CSF NfL showed a negative correlation with changes in
SCP volumes over 1 year in a subset of patients in the
recent davunetide trial.8 CSF NfL levels have also accom-
panied neuroimaging changes in other neurological con-
ditions. For example, CSF NfL levels showed negative
correlations with frontal, temporal, parietal, occipital, and
cingulate gray matter density in frontotemporal demen-
tia.7 CSF NfL correlated with the number of T1, T2, and
enhancing lesions seen on MRI in a cohort of patients
with untreated multiple sclerosis.22 In addition, higher
baseline CSF NfL levels in multiple sclerosis patients have
been observe to correlate with lower brain volumes at
baseline and with higher T2 lesions counts after 1 year.24
Plasma NfL levels in PSP patients correlated with CSF
NfL levels at baseline and at 1-year follow-up. These data
are in agreement with previous observations of a strong
correlation between serum and CSF NfL levels in patients
with neurodegenerative conditions such as ALS and AD,
as well as in multiple sclerosis and Guillain–Barre syn-
drome, but not in normal controls.13,14 Detection of NfL
in blood likely reflects rising CSF NfL concentrations sec-
ondary to neuronal injury and blood–brain barrier dis-
ruption.9 Accordingly, NfL has been observed to be an
extremely sensitive marker of axonal injury, with elevated
Figure 4. High baseline plasma NfL levels in PSP are associated with more severe neurologic, functional and cognitive decline at 1 year follow-
up, Allon cohort. Graphs represent percent change in clinical scale scores in PSP patients with low (blue) and high (red) median plasma NfL levels
at baseline. *Fixed effects of baseline NfL level at the specified time point, P < 0.05. NfL, neurofilament light chain; PSP, progressive supranuclear
palsy; PSPRS, progressive supranuclear palsy rating scale score; SEADL, Schwab and England activities of daily living score; RBANS, repeatable
battery for the assessment of neuropsychological disease severity score.
Figure 5. Baseline plasma NfL levels predict higher brain atrophy at
1 year follow-up, Allon cohort. Median percent decrease in regional
volume in PSP patients with low (blue, <36.7 pg/mL) and high (red,
≥36.7 pg/mL) baseline NfL concentrations. Error bars represent 95%
confidence intervals. *P < 0.05. NfL, neurofilament light chain; PSP,
progressive supranuclear palsy; SCP, superior cerebellar peduncle.
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concentrations measured after neuronal insults even in
the absence of clinical symptoms.10 The data presented
here add to the body of evidence supporting that NfL is a
biomarker of pathophysiologic relevance in PSP and may
be of value to track disease progression and outcomes.
There are several limitations in this study. The sample
size in the original cohort was limited and the diagnostic
sensitivity of plasma NfL could not be confirmed in the
validation cohort, since it did not include control sub-
jects. In addition, although patients and controls were
matched for age in the UCSF cohort, disease duration is
difficult to accurately determine in PSP participants due
to the retrospective nature of the research diagnostic cri-
teria. This raises the possibility that plasma NfL measure-
ment may have limited diagnostic sensitivity for patients
in early stages of the disease. Most PSP subjects lacked
neuropathological diagnostic confirmation. It is therefore
possible that a small number of subjects may not have
underlying PSP pathology. Nevertheless, a strength of the
diagnostic criteria for PSP is that they are highly predic-
tive of underlying PSP or 4R tau pathology.25 Although
PSP pathology was confirmed in all cases for which
autopsy was available, additional studies in controls,
atypical parkinsonism, and PD will be necessary to fully
establish the diagnostic sensitivity of plasma NfL for PSP.
Mean baseline plasma NfL levels were 29.1% higher in
the Allon cohort than in the UCSF cohort. It is sus-
pected that biological differences contributed significantly
to this discrepancy. The mean interval between symptom
onset and baseline sample collection was 5.3 years in the
UCSF cohort, but this interval was not determined in
the Allon cohort, making it possible that samples in the
Allon cohort were collected at a different point in the
natural history of the disease. This is supported by differ-
ences between cohorts observed in CSF total tau and
NfL. This limitation is important because NfL was only
measured at two time points per subject over 1 year.
Control for interval of disease onset to sampling, and
more frequent plasma sampling and prolonged follow-up
periods will be needed to determine the utility of plasma
NfL as a marker of disease progression. Variability was
likely not due to immunoassay-related variables as all
samples were run using the same ELISA kit batch. Never-
theless, measurements could have been affected by varia-
tions in sample handling conditions that were not
controlled, such as time of sample collection, length of
exposure to room temperature, or length of frozen stor-
age. Further testing that accounts for these variables
should also be conducted to assess the external validity
of plasma NfL measurements for diagnostic or prognostic
purposes. Although the available number of CSF samples
to correlate with plasma NfL levels was only a fraction of
the Allon cohort, CSF and plasma NfL values showed
robust correlations at baseline and follow-up, and they
were consistent with previous reports.13,14
This study suggests that measurement of plasma NfL con-
centrations is feasible and may be of value for monitoring
PSP disease activity and determining prognosis in clinically
diagnosed PSP patients. A strength of this study was that
our validation cohort was derived from a large, multicenter
clinical trial, suggesting that plasma NfL concentration may
be useful for monitoring the effects of therapeutic interven-
tions in PSP. This biomarker is being increasingly employed
in clinical trials in other neurological diseases. For example,
CSF NfL levels in patients with multiple sclerosis receiving
treatment were unchanged at 1 year follow-up, while
patients receiving placebo showed significant increases.24
Similarly, CSF NfL levels have been shown to be sensitive to
therapeutic interventions in paraneoplastic disease26 and
central nervous system HIV infection.27 Clinical trials of
new tau directed agents are increasingly being pursued in
PSP.8,28 Since PSP is a rare disease in which CSF and MRI
data can be difficult to collect due to patient factors (e.g.,
axial rigidity) and geographic dispersion, the availability of
a peripheral biomarker of disease activity, such as plasma
NfL, could greatly accelerate therapeutic development.
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